Listening to patients has been at the heart of GW’s research efforts since our company’s founding in 1998. GW’s initial research efforts in the UK focused on responding to the needs of patients with Multiple Sclerosis (MS) and resulted in the world’s first prescription cannabidiol product.
In recent years, GW has focused its efforts on the development of a potential new treatment option for seizures associated with severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS) and Tuberous Sclerosis Complex (TSC).
Maintaining our focus on the potential benefit to patients has been a consistent driving force in GW’s research program and progress to date. GW is in a unique position to develop and manufacture consistent cannabinoid formulations worldwide at sufficient quality, uniformity, scale and sophistication to meet international regulatory requirements.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.